centrosomal protein 112Genealiases: CCDC46 · MACOCO · SPGF44
Q-omics provides the consensus-scored CEP112 profile across patient tissues and cancer cell-line models. CEP112 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CEP112 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CEP112 RNA expression shows 20,305 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, KIRC, and KIRP as cancer lineages where CEP112 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP112 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP112 survival associations across molecular data types. CEP112 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP112 RNA expression–survival associations across cancer types. High CEP112 expression shows unfavorable associations in HNSC, LGG, ACC, LUSC and KIRP, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CEP112 RNA expression.
This table summarizes CEP112 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CEP112. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP112 shows lower tumor expression in KICH, LUSC and BLCA and higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher CEP112 RNA expression in tumor versus normal tissue (log2 FC = +0.705, t-test p < 0.001).
This table shows molecular features associated with CEP112 in patient tissues and cancer cell lines. In patient samples, CEP112 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP112 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
